

A005 - THROMBOCYTOSIS IN ADULT PATIENTS

What is thrombocytosis?

Thrombocytosis is defined as a high number of circulating platelets in the blood and is usually an incidental finding on a routine FBC.

What causes thrombocytosis?

This is due to **increased production** which can be a primary bone marrow problem (rare) or be secondary/reactive (very common) or **reduced destruction** due to hyposplenism.

Causes of raised platelets
Primary – clonal bone marrow disorders (myeloproliferative disorders)
Essential thrombocythaemia (ET) – isolated thrombocytosis
Polycythaemia vera (PV) – thrombocytosis with erythrocytosis
Myelofibrosis (MF) – thrombocytosis and anaemia (due to marrow fibrosis)
Chronic myeloid leukaemia (CML) - Philadelphia chromosome t(9;22) present
<i>Rarely as part of the myelodysplastic syndrome (platelets are usually low in MDS)</i>
Secondary ('reactive') – bone marrow is normal
Infection (acute or chronic)
Inflammatory disorders e.g. inflammatory bowel disease, arthritis, connective tissue disorders
Acute blood loss
Chronic blood loss / iron deficiency
Trauma or surgery
Malignancy
Rebound following chemotherapy
Splenectomy/hyposplenism (<i>due to decreased removal from the blood</i>)

What investigations should be performed in patients with persistent thrombocytosis?

(platelets $>450 \times 10^9/L$ over 2-3 months)

- History – splenectomy; blood loss; inflammatory disorder; chronic infection; thrombosis; occult malignancy
- Examination – spleen, evidence inflammation/infection/malignancy
- FBC – review if other cells raised
- Ferritin/iron studies – iron deficient
- CRP/ESR
- Autoantibody screen, rheumatoid factor (if inflammatory disease suspected)
- JAK2 mutation if no secondary cause (available via ICE – please state in clinical details that patient has thrombocytosis and CALR and MPL will be checked if JAK2 negative)

This is a controlled document and must be read in conjunction with all NNUH NHS Trust Policies and Procedures.
 It is the responsibility of the user to ensure that they are aware of the current issue and printed copies (including blank forms)
 can only be deemed current at the time of printing. Please notify any changes required to the document approver.

N.B If U and Es checked – there is often **spurious hyperkalaemia** in primary thrombocytosis – this is a laboratory anomaly caused by potassium leaking from platelets in storage. It does not affect the patient.

What problems do a secondary ('reactive') thrombocytosis cause?

Thrombus formation is extremely rare. It tends to occur in patients with platelet count more than $1000 \times 10^9/L$ plus other risk factors for thrombosis.

- complications of the underlying cause e.g. bleeding, are much more common

What treatments are given to patients with reactive thrombocytosis?

- treatment of the underlying condition
- patients with additional risk factors for thrombosis e.g. imminent surgery, may need antithrombotic measures e.g. compression stockings, aspirin or prophylactic heparin.

What problems result from thrombocytosis caused by a myeloproliferative disorder?

Patients are at increased risk of both thrombotic (arterial and venous) and haemorrhagic events. The most important risk factors for a thrombotic event are:

- age over 60 years
- history of thrombotic event
- presence of other risk factors for arterial vascular disease.

Haemorrhagic complications are less common but are more likely to occur if the platelet count is more than $1000 \times 10^9/L$ and very likely if it is $>1500 \times 10^9/L$.

What treatments are given to patients with a myeloproliferative disorder?

- watchful waiting +/- aspirin
- cytoreductive therapy e.g. hydroxycarbamide or anagrelide, and aspirin

When should I seek further advice or refer to haematology?

- patients positive for JAK2/CALR/MPL (request JAK2 via ICE)
- persistent thrombocytosis $\geq 600 \times 10^9/L$ over 6-8 weeks with no obvious reactive cause
- persistent thrombocytosis $\geq 450 \times 10^9/L$ associated with other full blood count abnormalities (*excluding* anaemia due to iron deficiency)
- persistent thrombocytosis $\geq 450 \times 10^9/L$ associated with thrombotic events
- thrombocytosis $\geq 450 \times 10^9/L$ associated with splenomegaly (either clinically or radiologically)

What follow up is recommended for patients not referred to haematology?

- asymptomatic patients with chronic reactive thrombocytosis do not require regular FBCs - although the platelet count may be a useful marker of the disease activity.
- if a reactive cause for thrombocytosis has not been identified, it may be prudent to recheck the patient's FBC every 3 to 6 months to ensure they are not developing a myeloproliferative disorder (rising platelet count – increase in other cell types).

What other advice should I give?

- patients should be asked to return for FBC if they develop thrombotic (e.g. TIAs) or haemorrhagic symptoms or left upper quadrant discomfort (might suggest splenomegaly).
- lifestyle should be reviewed and risk factors for arterial/venous thrombosis addressed.

References

This is a controlled document and must be read in conjunction with all NNUH NHS Trust Policies and Procedures. It is the responsibility of the user to ensure that they are aware of the current issue and printed copies (including blank forms) can only be deemed current at the time of printing. Please notify any changes required to the document approver.

Guideline for investigation and management of adults and children presenting with thrombocytosis
– Claire Harrison et al. British Journal Haematology 2010, 149, 352-375
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08122.x/full>

This is a controlled document and must be read in conjunction with all NNUH NHS Trust Policies and Procedures.

It is the responsibility of the user to ensure that they are aware of the current issue and printed copies (including blank forms) can only be deemed current at the time of printing. Please notify any changes required to the document approver.

Title: Thrombocytosis Advice

Page 3 of 3

Review date: 09 04 2023 by AC/MJL

Document reference: H.A005.v8

Trust Document 4646